🇺🇸 FDA
Patent

US 11691972

Compounds for targeted degradation of BRD9

granted A61KA61K45/06A61P

Quick answer

US patent 11691972 (Compounds for targeted degradation of BRD9) held by C4 THERAPEUTICS, INC. expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
C4 THERAPEUTICS, INC.
Grant date
Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K45/06, A61P, A61P35/00